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Abstract. Cold atmospheric plasma (CAP) has shown its promising application in cancer 
treatment both in vitro and in vivo. However, the anti-cancer mechanism is still largely unknown. 
CAP may kill cancer cells via triggering the rise of intracellular ROS, DNA damage, mitochondrial 
damage, or cellular membrane damage. While, the specific vulnerability of cancer cells to CAP 
has been observed, the underlying mechanism of such cell-based specific vulnerability to CAP is 
completely unknown. Here, through the comparison of CAP treatment and H2O2 treatment on 10 
different cancer cell lines in vitro, we observed that the H2O2 consumption speed by cancer cells 
was strongly correlated to the cytotoxicity of CAP treatment on cancer cells. Cancer cells that clear 
extracellular H2O2 more quickly are more resistant to the cytotoxicity of CAP treatment. This 
finding strongly indicates that the anti-oxidant system in cancer cells play a key role in the specific 
vulnerability of cancer cells to CAP treatment in vitro.  
 
Introduction.   
As a near-room temperature ionized gas, cold atmospheric plasma (CAP) has demonstrated its 
promising application in cancer treatment by causing the selective death of cancer cells in vitro 
[1–3]. The CAP treatment on several subcutaneous xenograft tumors and melanoma in mice has 
also demonstrated its potential clinical application [4–7]. The rise of intracellular ROS, DNA 
damage, mitochondrial damage, as well as apoptosis have been extensively observed in the CAP-
treated cancer cell lines [8–10]. The increase of intracellular ROS may be due to the complicated 
intracellular pathways or the diffusion of extracellular ROS through the cellular membrane [11]. 
However, the exact underlying mechanism is still far from clear.  
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Cancer cells have shown specific vulnerabilities to CAP [12]. Understanding the vulnerability of 
cancer cells to CAP will provide key guidelines for its application in cancer treatment. Two general 
trends about the cancer cells’ vulnerability to CAP treatment have been observed in vitro. First, 
the cancer cells expressing the p53 gene are more resistant to CAP treatment than p53 minus cancer 
cells [13]. p53, a key tumor suppressor gene, not only restricts abnormal cells via the induction of 
growth arrest or apoptosis, but also protects the genome from the oxidative damage of ROS such 
as H2O2 through regulating the intracellular redox state [14]. p53 is an upstream regulator of the 
expression of many anti-oxidant enzymes such as glutathione peroxidase (GPX), glutaredoxin 3 
(Grx3), and manganese superoxide dismutase (MnSOD) [15]. In addition, cancer cells with a lower 
proliferation rate are more resistant to CAP than  cancer cells with a higher proliferation rate [16]. 
This trend may be due to the general observation that the loss of p53 is a key step during 
tumorigenesis [17]. Tumors at a high tumorigenic stage are more likely to have lost p53 [17].  
 
Despite the complicated interaction between CAP and cancer cells, the initial several hours after 
treatment has been found to be an important stage for the cytotoxicity of CAP. The anti-cancer 
ROS molecules in the extracellular medium are completely consumed by cells during this time 
period [12]. After the initial several hours, replacing the medium surrounding the cancer cells does 
not change the cytotoxicity of CAP [18]. Here, we first demonstrate that the H2O2 consumption 
speed of cancer cells after CAP treatment is a key factor determining the specific vulnerability of 
cancer cell lines to CAP. The higher H2O2 consumption speed of cancer cells during the initial 3 
hours after CAP treatment, results in a less degree of cytotoxicity with CAP treatment. Cancer 
cells having the capacity to quickly clear the extracellular ROS are more likely to survive 
compared with other cells which consume the extracellular ROS more slowly.  
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Methods and materials.  
CAP device. The CAP device used in this study is a typical CAP jet generator using helium as the 
carrying gas. The detailed description of this device has been illustrated in previous studies [12,19]. 
Briefly, a violet plasma jet is formed below the main discharge area between a central anode and 
an annular grounded cathode and flows out a quartz tube with a diameter of 4.5 mm. The discharge 
is driven by a 30 kHz alternating current voltage (3.02 kV). The flow rate of the carrying gas is 
about 4.7 L/min.  
 
Cell cultures. Human pancreas ductal adenocarcinoma cell line (PANC-1) was purchased from 
American Type Culture Collection (ATCC). Other cell lines were donated by several labs at the 
George Washington University. These cells were all purchased from ATCC by the different labs. 
Human pancreatic adenocarcinoma cell line (PA-TU-8988T), human glioblastoma cell line 
(U87MG), as well as human lung carcinoma cell line (A549) were provided by Dr. Murad’s lab. 
Human breast cancer cell lines (MDA-MB-231, MCF-7) were provided by Dr. Zhang’s lab. 
Human ovarian carcinoma cell line (SK-OV-3), human ovarian carcinoma cell line (IGROV-1), 
human colorectal carcinoma cell line (HCT116), as well as human bone osteosarcoma cell line (U-
2 OS) were provided by Dr. Zhu’s lab. Murine melanoma cell line (B16F10) was provided by Dr. 
Sotomayor’s lab. The medium used in the culture of B16F10 cells was composed of RPMI-1640 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, S11150) and 1% (v/v) penicillin 
and streptomycin solution (Life Technologies, 15140122). All other cells were cultured in DMEM 
supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin and streptomycin solution. 
For each experiment, 3x103 cells were seeded per well on a 96-well plate (Falcon, 62406-081) and 
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cultured 24 hours under standard culture conditions (a humidified, 37°C, 5% CO2 environment) 
prior to CAP treatment.   
 
CAP treatment and H2O2 treatment on cancer cells. Prior to CAP treatment, all entire medium 
used to culture cells overnight was removed. To perform the direct CAP treatment, the gap between 
the bottom of the 96-well plate and the CAP source was 3 cm. Subsequently, 100 μL of fresh 
DMEM or RPMI-1640 (only for B16F10 cells) was added to the cancer cells in the 96-well plate. 
The CAP jet was then used to vertically treat each well for 1 min, 2 min, or 3 min. H2O2-containing 
medium was made by adding 9.8 M H2O2 standard solution (216763, Sigma-Aldrich) in DMEM 
or RPMI-1640 (only for B16F10 cells). 100 μL of H2O2-containing medium was then added to the 
cancer cells. After direct CAP and H2O2 treatment, the cancer cells were cultured under standard 
conditions for 3 days prior to performing the cell viability assay. In all cases, the control group 
consisted of cancer cells grown in fresh DMEM without CAP or H2O2 treatment.  
 
Cell viability assay. MTT (3-(4,5-Dimethyl-2-thiazol)-2,5-Diphenyl-2H-tetrazolium Bromide) 
assay was performed following the standard protocols provided by Sigma-Aldrich. The absorbance 
at 570 nm was measured by a H1 microplate reader (Hybrid Technology). The measured 
absorbance was processed to be a relative cell viability by the division between the data of the 
experimental group and the control group.  
 
Extracellular H2O2 assay. The H2O2 concentration was measured using the Fluorimetric 
Hydrogen Peroxide Assay Kit (Sigma-Aldrich, MAK165-1KT) using standard protocols provided 
by Sigma-Aldrich. The fluorescence was measured by a H1 microplate reader (Hybrid Technology) 
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at 540/590 nm. The final fluorescence was obtained by deducting the fluorescence of control group 
from the fluorescence of experimental group. The H2O2 concentration was obtained based on the 
standard curve.  
 
Measuring the H2O2 consumption speed by cancer cells. The CAP-stimulated DMEM (PSM) 
was made by treating 8 mL DMEM in the well on a 6-well plate for 8 min. H2O2-containing 
DMEM was made as above. The same protocol was used on all cell lines. First, 100 μL of cells at 
a concentration of 6x104 cells/mL was seeded in each well. 3 wells were used for each test. Cells 
were then cultured for 24 hours under standard conditions. 100 μL of sample solution was added 
to the wells. After 3 hours, 50 μL of medium was collected and immediately transferred to a well 
on a black clear bottom 96-well plate (Falcon) and the H2O2 assay was then performed every hour 
in triplicate.  
 
Results and discussion.  
The initial several hours are the most important stage for determining the cytotoxicity of CAP on 
cancer cells [10,12,18]. Our previous studies have demonstrated that key reactive species such as 
H2O2 in the medium is completely consumed by glioblastoma cells in just 3 hours [10,12,18]. Here, 
we comprehensively compared the H2O2 consumption speeds of 10 cancer cell lines during their 
initial 3 hours cultured in the CAP-stimulated medium, which was used to quantify the ROS-
scavenging ability of cancer cells. We measured the residual H2O2 in the medium surrounding the 
cells every hour after treatment for 3 hours. The relative residual H2O2 concentration was obtained 
by the division between the residual H2O2 concentration and the initial H2O2 generation in DMEM.  
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We found that the H2O2 consumption speed is cell specific. In the CAP-treated DMEM, B16F10 
cells and SK-OV-3 cells consume H2O2 fastest among all 10 cell lines (Fig. 1a). B16F10 cells and 
SK-OV-3 cells clear all extracellular H2O2 in only 2 hours. U2 OS cells consume extracellular 
H2O2 the slowest (Fig. 1a). U2 OS cells only consume about 70% of extracellular H2O2 in three 
hours after CAP treatment. In addition, PA-TU-8998T, MCF-7 HCT116, and IGROV-1 cells have 
a similar but higher H2O2 consumption rates compared to U2 OS cells (Fig. 1a).   
 
In addition, the 10 cancer cell lines showed specific vulnerability to direct CAP treatment. Due to 
the potential cell-based H2O2 generation during direct CAP treatment, the CAP device was used 
at a relatively low discharge voltage (3.02 kV). At such a low voltage, the cell-based H2O2 
generation can be inhibited [20]. Thus, the initial reactive species input from CAP is the same 
among all cell lines. Among these cell lines, B16F10 and SK-OV-3 cells are most resistant to CAP 
treatment (Fig. 1b). A 3 min of CAP treatment led to only a 50% inhibition of cell viability in 
B16F10 cells compared with control. In contrast, U2OS, PA-TU-8998T, MCF-7, and HCT116 
cells are the most vulnerable to direct CAP treatment (Fig. 1b). Clearly, these cancer cell lines 
have the least extracellular H2O2 consumption rates (Fig. 1a). The remaining cell lines generally 
follow this trend, in that the extracellular ROS scavenging ability of cancer cells is inversely 
proportional to their vulnerabilities to CAP treatment.  
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Fig. 1. The effect of CAP treatment on 10 cancer cell lines. (a) The evolution of H2O2 in the 
extracellular environment due to the consumption of cancer cells. H2O2 was generated by the CAP 
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treatment on the medium. (b) The cytotoxicity of direct CAP treatment on cancer cells grown on 
96-well plates. The results are presented as the mean of three independent experiments performed 
in triplicate. The measured H2O2 concentration in the CAP-treated medium was 48.8 ± 6.5 μM. 
The original data with standard deviation are shown in supporting materials (Fig. S1 and S2).  
 
This trend was preserved when cancer cell lines were grown in H2O2-containing medium. All 10 
cancer cells showed nearly the same specific H2O2 consumption rates in the H2O2-containing 
medium as that observed in the CAP-stimulated medium (Fig. 2a). Similar, the vulnerability of 
cancer cells to H2O2 treatment is also inversely proportional to the H2O2 consumption rate of 
cancer cells (Fig. 2b). For example, B16F10 cells, simultaneously has the strongest H2O2-
scavenging capacity and the strongest resistance to H2O2 treatment. As we observed in previous 
studies, however, CAP treatment cannot be regarded as a simple H2O2 treatment [12]. B16F10 
cells are much more resistant to H2O2 treatment than all other cell lines include-ing SK-OV-3 cells 
(Fig. 2b). Instead, the vulnerability difference between B16F10 cells and SK-OV-3 cells during 
H2O2 treatment are much larger than that observed during CAP treatment. This difference may be 
due to the complicated ROS and RNS components generated in CAP treatment, which will never 
be generated by just a H2O2 treatment [21,22]. Nonetheless, the same trends observed in Fig. 1 and 
Fig. 2 clearly demonstrate that the ROS-scavenging potential of cancer cells may play key a role 
in the specific cytotoxicity of the extracellular ROS treatment of both CAP and H2O2 treatment.  
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Fig. 2. The effect of H2O2 treatment on 10 cancer cell lines. (a) The evolution of H2O2 in the 
extracellular environment due to its consumption by cancer cells. The initial H2O2 concentration 
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was 53.3 ± 9.1 μM, which was the H2O2 concentration generated in the 8 mL medium after 8 min 
of CAP treatment. (b) The cytotoxicity of H2O2 treatment on cancer cells. The H2O2 concentrations 
shown here are the integral multiples of 53.3 μM. The results are presented as the mean of three 
independent experiments performed in triplicate. The original data with standard deviation are 
shown in supporting materials (Fig. S3 and S4). 
 
The correlation between the H2O2 consumption potential of cancer cells and the cytotoxicity of 
CAP treatment or H2O2 treatment on cancer cells is summarized and shown in Fig. 3. The inversely 
proportional correlation between the H2O2 consumption rate and the cytotoxicity of CAP is more 
pronounced in the case of the CAP treatment (Fig. 3a) than that of the H2O2 treatment (Fig. 3b). 
Our finding provides a simple cellular marker to predict the cytotoxicity of CAP treatment on 
different cancer cells. To date, investigating the expression of p53 gene in cancer cells is the only 
general method to predict the specific cytotoxicity of CAP treatment. The cancer cells expressing 
p53 gene tend to be more resistant to CAP treatment compared to the cells without the p53 gene 
[13]. However, this strategy needs complicated biochemical analysis such as western blot and PCR. 
In contrast, our strategy needs only a measure of the extracellular H2O2 generation during the initial 
several hours including the first hour post CAP treatment. This is the first attempt to connect the 
previous observed complicated vulnerabilities of different cancer cells to CAP treatment with a 
clear but easily measurable cellular feature.  
 
The H2O2 consumption speed of cancer cells may be the explanation at the cellular level for the 
correlation between the expression of p53 gene and the specific cytotoxicity of CAP treatment. 
p53 regulates the expression of the anti-oxidant system [15]. Thus, the vulnerability of cancer cells 
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to CAP treatment may be significantly affected by the intracellular anti-oxidant system. For 
example, A549 and U87MG cells are known as peroxide-resistant cell lines [23]. The 
overexpression of the bcl-2 and the related bcl-xL protooncogene proteins and catalase may 
contribute to their H2O2-resistant feature through inhibiting apoptosis induced by oxidants and the 
scavenging  intracellular H2O2, respectively [23]. The catalase activity is a major determinant of 
the cellular resistance to H2O2 toxicity [24]. The specific catalase expression levels in cancer cells 
may explain the correlation between the specific H2O2 consumption speed of cancer cells and the 
specific vulnerability of cancer cells to CAP treatment or H2O2 treatment. This explanation is 
consistent with our previous model that catalase may play an important role in the selective anti-
cancer capacity of CAP, since cancer cells tend to express less catalase compared with their 
corresponding homologous normal cell lines in many cases [1].  
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Fig. 3. The inversely proportional correlation between the H2O2 consumption rates of cancer 
cells and the growth inhibition effect of CAP treatment or H2O2 treatment on cancer cells. 
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(a) CAP treatment. (b) H2O2 treatment. The red lines are the trend lines drawn by Excel 2016. The 
H2O2 consumption rate and the growth inhibition rate were calculated based on the following 
formulas. The H2O2 consumption rate (%) = 100 x (1-the residual H2O2 concentration measured 
at the 1st hour post the treatment). The residual H2O2 concentration was shown in Fig. 1a, and Fig. 
2a. For CAP treatment, the growth inhibition rate (%) = 100 x (1 - relative cell viability [1 min of 
CAP treatment, Fig. 1b]). For H2O2 treatment, the growth inhibition rate (%) = 100 x (1 - relative 
cell viability [53.3 μM of H2O2 treatment, Fig. 2b]). 
 
Conclusions.  
The H2O2 consumption rate of cancer cells is an important cellular physiological marker to predict 
the cytotoxicity of CAP treatment or H2O2 treatment on cancer cell lines in vitro. The cancer cells 
which can clear the extracellular H2O2 at a faster rate tend to show stronger resistance to CAP 
treatment or H2O2 treatment. This trend firstly provides a simple cellular marker to correlate the 
vulnerability of cancer cells to CAP treatment. The measurement on the evolution of H2O2 during 
the initial several hours post CAP treatment can predict the final cytotoxicity of CAP treatment on 
cancer cells in vitro. The specific expression of intracellular anti-oxidant systems may contribute 
to such a unique correlation in cancer cells.  
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